Compare TRNR & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRNR | ENVB |
|---|---|---|
| Founded | 2017 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 3.0M |
| IPO Year | 2023 | N/A |
| Metric | TRNR | ENVB |
|---|---|---|
| Price | $0.62 | $4.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $120.00 |
| AVG Volume (30 Days) | ★ 2.6M | 53.6K |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,774,000.00 | N/A |
| Revenue This Year | $245.67 | N/A |
| Revenue Next Year | $308.85 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 207.36 | N/A |
| 52 Week Low | $0.61 | $3.50 |
| 52 Week High | $39.60 | $61.18 |
| Indicator | TRNR | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 24.69 | 48.10 |
| Support Level | $0.64 | $3.76 |
| Resistance Level | $1.62 | $4.24 |
| Average True Range (ATR) | 0.15 | 0.28 |
| MACD | 0.00 | 0.08 |
| Stochastic Oscillator | 0.66 | 88.72 |
Interactive Strength Inc provides an integrated home fitness platform that allows its customers to participate in interactive wellness and strength-based training sessions. Its health coaching services encompass guidance and coaching on nutrition, recovery, sleep, and other health and lifestyle categories. The company generates revenue from sales of its connected fitness products, membership revenue, and personal training revenue.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.